TRAILR2/CDH3 bispecific antibody (Boehringer Ingelheim)

N/A

Report date: 2025/06/19 11:38:47

Base Information

Drug NameTRAILR2/CDH3 bispecific antibody (Boehringer Ingelheim)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-DR5Anti-Cadherin 3

TargetsTumor necrosis factor receptor superfamily member 10BCadherin 3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBoehringer Ingelheim International Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesBoehringer Ingelheim International Gmbh

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A